Incyte (INCY) Return on Capital Employed (2011 - 2026)
Incyte (INCY) posted Return on Capital Employed of 28.47% for Q1 2026, down 3.62% on a QoQ basis from 29.54% in Q4 2025, and up 2396.0% year-over-year from 1.14% in Q1 2025.
Incyte (INCY) Return on Capital Employed (2011 - 2026) Analysis & Trends
Incyte's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 28.47% for Q1 2026.
- Quarterly Return on Capital Employed rose 2396.0% year-over-year to 28.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 28.47% (up 2396.0% YoY) and the FY2025 annual result came in at 32.33%, up 3096.0% from the prior year.
- Return on Capital Employed was 28.47% for Q1 2026 at Incyte, down from 29.54% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 31.25% in Q3 2025 and bottomed at 1.59% in Q3 2024.
- A 5-year average of 13.62% and a median of 12.36% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed sank 1131 bps — and 2025, when it jumped 3284 bps.
- Incyte's Return on Capital Employed stood at 12.82% in 2022, then fell by 9 bps to 11.61% in 2023, then sank by 85 bps to 1.71% in 2024, then soared by 1626 bps to 29.54% in 2025, then dropped by 4 bps to 28.47% in 2026.
- Business Quant data shows INCY's Return on Capital Employed at 28.47% in Q1 2026, 29.54% in Q4 2025, and 31.25% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Incyte | 23.33 Bn | 19.32 Bn | 1.17 Bn | 28.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.47% |
| Dec 31, 2025 | 29.54% |
| Sep 30, 2025 | 31.25% |
| Jun 30, 2025 | 26.25% |
| Mar 31, 2025 | 4.50% |
| Dec 31, 2024 | 1.71% |
| Sep 30, 2024 | -1.59% |
| Jun 30, 2024 | 0.35% |
| Mar 31, 2024 | 12.36% |
| Dec 31, 2023 | 11.61% |
| Sep 30, 2023 | 9.73% |
| Jun 30, 2023 | 8.74% |
| Mar 31, 2023 | 10.13% |
| Dec 31, 2022 | 12.82% |
| Sep 30, 2022 | 14.07% |
| Jun 30, 2022 | 16.83% |
| Mar 31, 2022 | 14.69% |
| Dec 31, 2021 | 15.78% |
| Sep 30, 2021 | 19.32% |
| Jun 30, 2021 | 13.10% |